AGIOS PHARMACEUTICALS, INC. Research and Development Expense
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Research and Development Expense of $100.75 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-30
- AGIOS PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $100.75M, a 9.59% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-03-31 was $81.15M, a 11.55% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-12-31 was $88.06M, a 6.33% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-09-30 was $86.80M, a 19.79% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $339.54M, a 12.70% increase from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $301.29M, a 1.95% increase from fiscal 2023.
- AGIOS PHARMACEUTICALS, INC. research and development expense for fiscal 2023 was $295.53M, a 5.58% increase from fiscal 2022.
- AGIOS PHARMACEUTICALS, INC. research and development expense for fiscal 2022 was $279.91M, a 8.93% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $100.75M 10-Q · filed 2026-07-30 | $181.90M 10-Q · filed 2026-07-30 | $269.96M derived: sum of 3 quarters · filed 2026-07-30 | $356.75M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $81.15M 10-Q · filed 2026-04-29 | $169.20M derived: sum of 2 quarters · filed 2026-04-29 | $256.00M derived: sum of 3 quarters · filed 2026-04-29 | $347.94M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $88.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $174.85M derived: sum of 2 quarters · filed 2026-02-12 | $266.79M derived: sum of 3 quarters · filed 2026-07-30 | $339.54M 10-K · filed 2026-02-12 | ||||
| 2025-09-30 | $86.80M 10-Q · filed 2025-10-30 | $178.74M derived: sum of 2 quarters · filed 2026-07-30 | $251.48M 10-Q · filed 2025-10-30 | $334.29M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $91.94M 10-Q · filed 2026-07-30 | $164.68M 10-Q · filed 2026-07-30 | $247.49M derived: sum of 3 quarters · filed 2026-07-30 | $319.95M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $72.74M 10-Q · filed 2026-04-29 | $155.55M derived: sum of 2 quarters · filed 2026-04-29 | $228.01M derived: sum of 3 quarters · filed 2026-04-29 | $305.41M derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2024-12-31 | $82.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $155.26M derived: sum of 2 quarters · filed 2026-02-12 | $232.67M derived: sum of 3 quarters · filed 2026-02-12 | $301.29M 10-K · filed 2026-02-12 | ||||
| 2024-09-30 | $72.45M 10-Q · filed 2025-10-30 | $149.86M derived: sum of 2 quarters · filed 2025-10-30 | $218.48M 10-Q · filed 2025-10-30 | $295.96M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-06-30 | $77.40M 10-Q · filed 2025-07-31 | $146.02M 10-Q · filed 2025-07-31 | $223.51M derived: sum of 3 quarters · filed 2026-02-12 | $305.35M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-03-31 | $68.62M 10-Q · filed 2025-05-01 | $146.11M derived: sum of 2 quarters · filed 2026-02-12 | $227.95M derived: sum of 3 quarters · filed 2026-02-12 | $296.85M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2023-12-31 | $77.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $159.33M derived: sum of 2 quarters · filed 2026-02-12 | $228.22M derived: sum of 3 quarters · filed 2026-02-12 | $295.53M 10-K · filed 2026-02-12 | ||||
| 2023-09-30 | $81.84M 10-Q · filed 2024-10-31 | $150.74M derived: sum of 2 quarters · filed 2024-10-31 | $218.04M 10-Q · filed 2024-10-31 | $288.33M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | $68.89M 10-Q · filed 2024-08-01 | $136.20M 10-Q · filed 2024-08-01 | $206.49M derived: sum of 3 quarters · filed 2025-02-13 | $271.46M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $67.30M 10-Q · filed 2024-05-02 | $137.60M derived: sum of 2 quarters · filed 2025-02-13 | $202.56M derived: sum of 3 quarters · filed 2025-02-13 | $277.09M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | $70.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $135.26M derived: sum of 2 quarters · filed 2025-02-13 | $209.79M derived: sum of 3 quarters · filed 2025-02-13 | $279.91M 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $64.97M 10-Q · filed 2023-11-02 | $139.49M derived: sum of 2 quarters · filed 2023-11-02 | $209.61M 10-Q · filed 2023-11-02 | $282.91M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | $74.52M 10-Q · filed 2023-08-03 | $144.65M 10-Q · filed 2023-08-03 | $217.94M derived: sum of 3 quarters · filed 2024-02-15 | $281.94M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | $70.12M 10-Q · filed 2023-05-04 | $143.42M derived: sum of 2 quarters · filed 2024-02-15 | $207.42M derived: sum of 3 quarters · filed 2024-02-15 | $269.43M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $73.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $137.30M derived: sum of 2 quarters · filed 2024-02-15 | $199.31M derived: sum of 3 quarters · filed 2024-02-15 | $256.97M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $64.00M 10-Q · filed 2022-11-03 | $126.01M derived: sum of 2 quarters · filed 2022-11-03 | $183.67M 10-Q · filed 2022-11-03 | $243.10M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-06-30 | $62.01M 10-Q · filed 2022-08-04 | $119.67M 10-Q · filed 2022-08-04 | $179.10M derived: sum of 3 quarters · filed 2023-02-23 | $231.04M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-03-31 | $57.67M 10-Q · filed 2022-05-05 | $117.09M derived: sum of 2 quarters · filed 2023-02-23 | $169.03M derived: sum of 3 quarters · filed 2023-02-23 | $223.12M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2020-12-31 | $59.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $111.37M derived: sum of 2 quarters · filed 2023-02-23 | $165.45M derived: sum of 3 quarters · filed 2023-02-23 | $220.81M 10-K · filed 2023-02-23 | $367.47M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $51.94M 10-Q · filed 2021-11-03 | $89.56M 10-Q · filed 2020-11-05 | $106.03M derived: sum of 2 quarters · filed 2021-11-03 | $161.39M 10-Q · filed 2021-11-03 | $271.73M 10-Q · filed 2020-11-05 | $71.00M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-06-30 | $54.09M 10-Q · filed 2021-07-29 | $90.92M 10-Q · filed 2020-07-30 | $109.44M 10-Q · filed 2021-07-29 | $182.17M 10-Q · filed 2020-07-30 | $19.06M derived: sum of 3 quarters · filed 2022-02-24 | $120.73M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-03-31 | $55.36M 10-Q · filed 2021-04-29 | $91.26M 10-Q · filed 2020-04-30 | -$35.03M derived: sum of 2 quarters · filed 2022-02-24 | $66.65M derived: sum of 3 quarters · filed 2022-02-24 | $174.03M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2019-12-31 | -$90.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $11.29M derived: sum of 2 quarters · filed 2022-02-24 | $118.68M derived: sum of 3 quarters · filed 2022-02-24 | $214.26M 10-K · filed 2022-02-24 | $410.89M 10-K · filed 2020-02-19 | |||
| 2019-09-30 | $101.67M 10-Q · filed 2020-11-05 | $209.06M derived: sum of 2 quarters · filed 2020-11-05 | $304.65M 10-Q · filed 2020-11-05 | $398.45M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $107.39M 10-Q · filed 2020-07-30 | $202.97M 10-Q · filed 2020-07-30 | $296.78M derived: sum of 3 quarters · filed 2021-02-25 | $379.34M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $95.58M 10-Q · filed 2020-04-30 | $189.39M derived: sum of 2 quarters · filed 2021-02-25 | $271.95M derived: sum of 3 quarters · filed 2021-02-25 | $358.69M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $93.81M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $176.37M derived: sum of 2 quarters · filed 2021-02-25 | $263.10M derived: sum of 3 quarters · filed 2021-02-25 | $341.32M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $82.56M 10-Q · filed 2019-10-31 | $169.29M derived: sum of 2 quarters · filed 2019-10-31 | $247.51M 10-Q · filed 2019-10-31 | $324.73M derived: sum of 4 quarters · filed 2020-02-19 | ||||
| 2018-06-30 | $86.73M 10-Q · filed 2019-08-01 | $164.95M 10-Q · filed 2019-08-01 | $242.17M derived: sum of 3 quarters · filed 2020-02-19 | $315.09M derived: sum of 4 quarters · filed 2020-02-19 | ||||
| 2018-03-31 | $78.22M 10-Q · filed 2019-05-02 | $155.44M derived: sum of 2 quarters · filed 2020-02-19 | $228.36M derived: sum of 3 quarters · filed 2020-02-19 | $308.17M derived: sum of 4 quarters · filed 2020-02-19 | ||||
| 2017-12-31 | $77.22M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $150.13M derived: sum of 2 quarters · filed 2020-02-19 | $229.95M derived: sum of 3 quarters · filed 2020-02-19 | $292.68M 10-K · filed 2020-02-19 | ||||
| 2017-09-30 | $72.92M 10-Q · filed 2018-11-01 | $152.73M derived: sum of 2 quarters · filed 2018-11-01 | $215.47M 10-Q · filed 2018-11-01 | $280.14M derived: sum of 4 quarters · filed 2019-02-14 | ||||
| 2017-06-30 | $79.82M 10-Q · filed 2018-08-02 | $142.55M 10-Q · filed 2018-08-02 | $207.23M derived: sum of 3 quarters · filed 2019-02-14 | $267.87M derived: sum of 4 quarters · filed 2019-02-14 | ||||
| 2017-03-31 | $62.73M 10-Q · filed 2018-05-04 | $127.41M derived: sum of 2 quarters · filed 2019-02-14 | $188.05M derived: sum of 3 quarters · filed 2019-02-14 | $238.86M derived: sum of 4 quarters · filed 2019-02-14 | ||||
| 2016-12-31 | $64.68M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $125.32M derived: sum of 2 quarters · filed 2019-02-14 | $176.13M derived: sum of 3 quarters · filed 2019-02-14 | $220.16M 10-K · filed 2019-02-14 | ||||
| 2016-09-30 | $60.64M 10-Q · filed 2017-11-01 | $111.45M derived: sum of 2 quarters · filed 2017-11-01 | $155.49M 10-Q · filed 2017-11-01 | $192.42M derived: sum of 4 quarters · filed 2018-02-14 | ||||
| 2016-06-30 | $50.80M 10-Q · filed 2017-08-08 | $94.84M 10-Q · filed 2017-08-08 | $131.78M derived: sum of 3 quarters · filed 2018-02-14 | $167.80M derived: sum of 4 quarters · filed 2018-02-14 | ||||
| 2016-03-31 | $44.04M 10-Q · filed 2017-05-04 | $80.97M derived: sum of 2 quarters · filed 2018-02-14 | $117.00M derived: sum of 3 quarters · filed 2018-02-14 | $153.42M derived: sum of 4 quarters · filed 2018-02-14 | ||||
| 2015-12-31 | $36.93M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | $72.96M derived: sum of 2 quarters · filed 2018-02-14 | $109.38M derived: sum of 3 quarters · filed 2018-02-14 | $141.83M 10-K · filed 2018-02-14 | ||||
| 2015-09-30 | $36.03M 10-Q · filed 2016-11-03 | $72.45M derived: sum of 2 quarters · filed 2016-11-03 | $104.89M 10-Q · filed 2016-11-03 | $139.76M derived: sum of 4 quarters · filed 2017-02-16 | ||||
| 2015-06-30 | $36.42M 10-Q · filed 2016-08-08 | $68.87M 10-Q · filed 2016-08-08 | $103.73M derived: sum of 3 quarters · filed 2017-02-16 | $129.25M derived: sum of 4 quarters · filed 2017-02-16 | ||||
| 2015-03-31 | $32.44M 10-Q · filed 2016-05-09 | $67.31M derived: sum of 2 quarters · filed 2017-02-16 | $92.83M derived: sum of 3 quarters · filed 2017-02-16 | $115.41M derived: sum of 4 quarters · filed 2017-02-16 | ||||
| 2014-12-31 | $34.86M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | $60.39M derived: sum of 2 quarters · filed 2017-02-16 | $82.96M derived: sum of 3 quarters · filed 2017-02-16 | $100.37M 10-K · filed 2017-02-16 | ||||
| 2014-09-30 | $25.53M 10-Q · filed 2015-11-06 | $48.10M derived: sum of 2 quarters · filed 2015-11-06 | $65.51M 10-Q · filed 2015-11-06 | $80.79M derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2014-06-30 | $22.58M 10-Q · filed 2015-08-07 | $39.98M 10-Q · filed 2015-08-07 | $55.26M derived: sum of 3 quarters · filed 2016-02-26 | $70.06M derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2014-03-31 | $17.41M 10-Q · filed 2015-05-11 | $32.69M derived: sum of 2 quarters · filed 2016-02-26 | $47.49M derived: sum of 3 quarters · filed 2016-02-26 | $60.45M derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2013-12-31 | $15.28M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $30.08M derived: sum of 2 quarters · filed 2016-02-26 | $43.04M derived: sum of 3 quarters · filed 2016-02-26 | $54.50M 10-K · filed 2016-02-26 | ||||
| 2013-09-30 | $14.80M 10-Q · filed 2014-11-07 | $27.76M derived: sum of 2 quarters · filed 2014-11-07 | $39.22M 10-Q · filed 2014-11-07 | $50.45M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-06-30 | $12.96M 10-Q · filed 2014-08-07 | $24.42M 10-Q · filed 2014-08-07 | $35.65M derived: sum of 3 quarters · filed 2015-02-24 | $45.44M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-03-31 | $11.46M 10-Q · filed 2014-05-09 | $22.69M derived: sum of 2 quarters · filed 2015-02-24 | $32.48M derived: sum of 3 quarters · filed 2015-02-24 | $42.95M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2012-12-31 | $11.22M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $21.02M derived: sum of 2 quarters · filed 2015-02-24 | $31.49M derived: sum of 3 quarters · filed 2015-02-24 | $41.04M 10-K · filed 2015-02-24 | ||||
| 2012-09-30 | $9.80M 10-Q · filed 2013-11-07 | $20.26M derived: sum of 2 quarters · filed 2013-11-07 | $29.81M 10-Q · filed 2013-11-07 | |||||
| 2012-06-30 | $10.46M 10-Q · filed 2013-09-05 | $20.01M 10-Q · filed 2013-09-05 | ||||||
| 2011-12-31 | $31.25M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |